/

Empresas

Mi

No verificado

MiraDx

Sobre qué escribimos

BiotecnologíaCienciaIndustriaOncologíaSalud

5 Comunicados de prensa

Ver todos los comunicados de prensa

18/12/2025

Industria

Oncología

Salud

Biotecnología

Ciencia

Farmacéutica

New Publication Shows PROSTOX™ ultra Test Delivers Significant Health System Cost Savings and Quality-of-Life Gains for Prostate Cancer Patients Undergoing Radiation Therapy

Fuente

Editor

1.00

0

01/10/2025

Biotecnología

Salud

Medicina nuclear

Oncología

Material médico sanitario

Ciencia

Ir de compras

Industria

MiraDx Announces the Commercial Availability of PROSTOX™ ultra for Prediction of Risk of Late Genitourinary Toxicity in Prostate Cancer Patients Considering Radiation Therapy

Fuente

Editor

1.00

0

26/09/2025

Eventos

Industria

Biotecnología

Salud

Ir de compras

Medicina nuclear

Biología

Oncología

Universidad

Ciencia

Material médico sanitario

Escuela/Educación

Medicina - Varios

MiraDx Announces New Research Conducted by UCLA and Other Academic Centers Presented at ASTRO 2025 that Confirms that Prostate Cancer Patients Identified as High-risk with PROSTOX™ ultra for SBRT Toxicity Can Safely Receive Other Radiation Regimens

Fuente

Editor

1.00

0

22/05/2025

Mercado laboral

Eventos

Industria

Ciencia

Biotecnología

Oncología

Salud

Material médico sanitario

Medicina - Varios

MiraDx Announces New Research Conducted in Collaboration with UCLA and Accepted for Presentation at ASCO 2025 that Highlights the Role of MicroRNA-based Genetic Signatures in Predicting Radiation and Immunotherapy Treatment-Related Outcomes

Fuente

Editor

1.00

0

07/04/2025

Industria

Ciencia

Biotecnología

Oncología

Salud

Material médico sanitario

Medicina - Varios

MiraDx Announces New Study Published in Clinical Cancer Research Validating PROSTOX™ ultra Diagnostic Test for Predicting Radiation-Induced Late Toxicity in Prostate Cancer

Fuente

Editor

1.00

0

Seguidores

0

Compatibilidad

0